Oesophageal Transplants: Pig Tissue Shows Promise for Children

A pioneering technique involving lab-grown oesophaguses, successfully implanted into pigs, is offering renewed hope for children born with a rare and life-threatening condition affecting their food pipe. The research, led by experts at Great Ormond Street Hospital (GOSH) and University College London (UCL), represents a significant step towards providing a potential treatment for babies born with long-gap oesophageal atresia (LGOA), a condition where the oesophagus – the tube connecting the mouth to the stomach – is separated by a significant gap.

Understanding Oesophageal Atresia and the Challenge of Repair

Oesophageal atresia, occurring in approximately 1 in 2,500 to 5,000 births, presents a complex surgical challenge. In cases of LGOA, the gap is too large to simply reconnect the existing oesophageal segments. Current surgical interventions often involve using parts of the stomach or intestines to bridge the gap, which can lead to long-term complications like breathing difficulties, gastric reflux, and an increased risk of cancer. The demand for alternative solutions has driven researchers to explore tissue engineering as a viable option. You can find more information about oesophageal atresia from the Great Ormond Street Hospital website.

How the Lab-Grown Oesophagus Was Created

The innovative approach developed by the GOSH and UCL team involves creating a ‘scaffold’ using a donor pig’s oesophagus. This scaffold is then stripped of all its original pig cells, essentially creating a blank tube. Scientists then grab muscle cells from the recipient pig and multiply them in the lab. These cells are injected directly into the scaffold, providing the building blocks for a new oesophagus. The tube is then placed in a specialized container where growth fluids are pumped through the tissue for a week, encouraging cell growth and tissue development.

Promising Results in Pig Trials

The study involved transplanting the lab-grown oesophaguses into eight pigs. Remarkably, all eight animals survived the initial 30-day period post-transplant. After six months, five pigs remained alive, and the engineered tissues had developed functional nerves, blood vessels, and muscle. This allowed the oesophagus to contract and move, mimicking the natural function of a food pipe. Importantly, the pigs were able to eat normally and maintain a healthy growth rate. The success in restoring normal swallowing function is a key indicator of the potential for this technology to translate to human patients. The research was published and summarized in The Independent.

Why Pig Tissue? And What About Human Application?

Researchers chose pig tissue as a scaffold as the pig oesophagus closely resembles the human one in terms of anatomy and function. Professor Paolo De Coppi, who led the research, explained that the oesophagus is a particularly challenging organ to transplant due to its lack of a dedicated blood supply. This makes traditional transplantation methods less effective, necessitating the development of alternative approaches like tissue engineering.

The team is now focused on preparing for human clinical trials, with the goal of offering this treatment to children within the next five years. The plan is to use a patient’s own cells grown on a pig oesophagus scaffold to create a personalized food pipe for transplantation. This approach aims to minimize the risk of rejection and maximize the chances of successful integration of the new oesophagus.

Limitations and Future Directions

Although the results are highly encouraging, it’s significant to acknowledge the limitations of the study. The research was conducted on pigs, and further studies are needed to confirm the safety and efficacy of this approach in humans. The long-term effects of the lab-grown oesophagus also need to be carefully evaluated. Professor De Coppi also noted that this technique is specifically designed for children with LGOA and wouldn’t be suitable for adults with other oesophageal problems, such as those caused by cancer, due to size constraints. The engineered oesophagus is intended to grow with the child, adapting to their changing needs.

The research team is also investigating ways to optimize the cell seeding process and improve the vascularization of the engineered tissue. Enhanced vascularization – the formation of new blood vessels – is crucial for ensuring the long-term survival and function of the transplanted oesophagus. Further research will also focus on refining the growth fluids and scaffold materials to create an even more conducive environment for tissue regeneration.

The Role of Professor Paolo De Coppi

Professor Paolo De Coppi is a leading figure in the field of paediatric surgery and regenerative medicine. As a Consultant Paediatric Surgeon at Great Ormond Street Hospital and Reader and Head of Stem Cells and Regenerative Medicine at the UCL Institute of Child Health, he has dedicated his career to developing innovative treatments for complex congenital anomalies. His operate on stem cells and tissue engineering has garnered international recognition, including a cover story in Nature Biotechnology in 2007. You can learn more about his work and expertise on the GOSH website.

What Comes Next: From Lab to Clinic

The next crucial step is securing regulatory approval to begin human clinical trials. This process will involve rigorous safety assessments and detailed protocols to ensure the well-being of participating children. Researchers will also need to establish robust manufacturing processes to produce the lab-grown oesophaguses at a scale sufficient to meet clinical demand. The team is actively collaborating with regulatory agencies and industry partners to navigate these challenges. The Yahoo News article highlights the five-year timeline for potential clinical application.

This research represents a beacon of hope for families affected by LGOA, offering the prospect of a life-changing treatment that could significantly improve the quality of life for these young patients. While challenges remain, the progress made by the GOSH and UCL team is a testament to the power of innovation in regenerative medicine.